Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 182

1.

Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.

Thangavelu G, Du J, Paz KG, Loschi M, Zaiken MC, Flynn R, Taylor PA, Kirchmeier AK, Panoskaltsis-Mortari A, Luznik L, MacDonald KP, Hill GR, Maillard I, Munn DH, Serody JS, Murphy WJ, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Dahlberg C, Miller AT, Blazar BR.

Blood. 2019 Oct 15. pii: blood.2019000032. doi: 10.1182/blood.2019000032. [Epub ahead of print]

PMID:
31697815
2.

Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, van den Brink M, Dong C, Huang S, Zang X, Allison JP, Zeiser R, Blazar BR.

JCI Insight. 2019 Oct 3;4(19). pii: 127716. doi: 10.1172/jci.insight.127716.

3.

Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.

Koehn BH, Saha A, McDonald-Hyman C, Loschi M, Thangavelu G, Ma L, Zaiken M, Dysthe J, Krepps W, Panthera J, Hippen K, Jameson SC, Miller JS, Cooper MA, Farady CJ, Iwawaki T, Ting JP, Serody JS, Murphy WJ, Hill GR, Murray PJ, Bronte V, Munn DH, Zeiser R, Blazar BR.

Blood. 2019 Nov 7;134(19):1670-1682. doi: 10.1182/blood.2019001950.

PMID:
31533918
4.

Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.

Nat Commun. 2019 Aug 15;10(1):3680. doi: 10.1038/s41467-019-11563-5.

5.

A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation?

Munn D, Abdul-Rahim AH, Fischer U, Werring DJ, Robinson TG, Dawson J.

Eur Stroke J. 2018 Dec;3(4):355-360. doi: 10.1177/2396987318787124. Epub 2018 Jul 10.

6.

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.

Nat Commun. 2019 Mar 20;10(1):1280. doi: 10.1038/s41467-019-09263-1. Erratum in: Nat Commun. 2019 Aug 15;10(1):3680.

7.

Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality.

Thangavelu G, Lee YC, Loschi M, Schaechter KM, Feser CJ, Koehn BH, Nowak EC, Zeiser R, Serody JS, Murphy WJ, Munn DH, Chambon P, Noelle RJ, Blazar BR.

J Immunol. 2019 May 1;202(9):2795-2805. doi: 10.4049/jimmunol.1800899. Epub 2019 Mar 18.

PMID:
30885956
8.

Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.

Am J Transplant. 2019 Jun;19(6):1820-1830. doi: 10.1111/ajt.15305. Epub 2019 Mar 19.

PMID:
30748099
9.

Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.

Munn DH, Sharma MD, Johnson TS.

Cancer Res. 2018 Sep 15;78(18):5191-5199. doi: 10.1158/0008-5472.CAN-18-1351. Epub 2018 Sep 4. Review.

10.

The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease.

McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, Kirchmeier AK, Osborn MJ, Hippen KL, Kelekar A, Serody JS, Turka LA, Munn DH, Chi H, Neubert TA, Dustin ML, Blazar BR.

J Clin Invest. 2018 Oct 1;128(10):4604-4621. doi: 10.1172/JCI95713. Epub 2018 Aug 14.

11.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN.

J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9.

12.

Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Habtetsion T, Ding ZC, Pi W, Li T, Lu C, Chen T, Xi C, Spartz H, Liu K, Hao Z, Mivechi N, Huo Y, Blazar BR, Munn DH, Zhou G.

Cell Metab. 2018 Aug 7;28(2):228-242.e6. doi: 10.1016/j.cmet.2018.05.012. Epub 2018 Jun 7.

13.

Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans.

Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, Deol R, Manion KP, Baglaenko Y, Eldh M, Lamorte S, Wallace D, Chodisetti SB, Ravishankar B, Liu H, Chaudhary K, Munn DH, Tsirigos A, Madaio M, Gabrielsson S, Touma Z, Wither J, De Carvalho DD, McGaha TL.

Nat Immunol. 2018 Jun;19(6):571-582. doi: 10.1038/s41590-018-0107-1. Epub 2018 May 14.

14.

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors.

Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, Bronte V, Wolchok JD, Blazar BR, Munn DH.

Immunity. 2018 Jan 16;48(1):91-106.e6. doi: 10.1016/j.immuni.2017.12.014.

15.

The host protecting the tumor from the host - targeting PD‑L1 expressed by host cells.

Munn DH.

J Clin Invest. 2018 Feb 1;128(2):570-572. doi: 10.1172/JCI99047. Epub 2018 Jan 16.

16.

Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Johnson TS, Mcgaha T, Munn DH.

Adv Exp Med Biol. 2017;1036:91-104. doi: 10.1007/978-3-319-67577-0_7. Review.

17.

A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.

Mangaonkar A, Mondal AK, Fulzule S, Pundkar C, Park EJ, Jillella A, Kota V, Xu H, Savage NM, Shi H, Munn D, Kolhe R.

Sci Rep. 2017 Oct 16;7(1):12892. doi: 10.1038/s41598-017-12940-0.

18.

Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells.

Ding ZC, Habtetsion T, Cao Y, Li T, Liu C, Kuczma M, Chen T, Hao Z, Bryan L, Munn DH, Zhou G.

Sci Rep. 2017 Sep 22;7(1):12168. doi: 10.1038/s41598-017-12488-z.

19.

IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.

Munn DH, Sharma MD, Johnson TS, Rodriguez P.

Cancer Immunol Immunother. 2017 Aug;66(8):1049-1058. doi: 10.1007/s00262-017-2010-2. Epub 2017 May 9. Review.

20.

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Turka LA, Kean LS, MacMillan ML, Miller JS, Wagner JE, Munn DH, Blazar BR.

Am J Transplant. 2017 Dec;17(12):3098-3113. doi: 10.1111/ajt.14338. Epub 2017 Jun 14.

Supplemental Content

Support Center